Supplement Dosage Form Myths vs Pharmacology

By Jack Zheng, MS Pharmacy -- Founder of MIHIYO Labs

Summary

Dosage form myths usually fail because they treat a delivery route as a multiplier that works equally for every ingredient. It does not. Absorption depends on the molecule, dose, dissolution, permeability, formulation, contact time, and the fraction actually swallowed. A 2024 crossover trial found one specific liposomal vitamin C product raised plasma peak concentration by 27% and 24-hour exposure by 21% versus standard vitamin C, not a universal tenfold gain. For MIHIYO Labs, an oral dissolving strip (ODS) is a design tool for suitable low-dose ingredients, convenient use, and controlled disintegration—not proof that every active becomes more bioavailable.

What is wrong with most supplement dosage form claims?

The central problem is simple: a dosage form is not a universal absorption multiplier. A capsule, liquid, liposome, powder, gummy, or oral dissolving strip (ODS) can change how an ingredient is released and presented to an absorbing surface. The result still depends on the ingredient and the finished formulation.

Bioavailability is the rate and extent to which an active reaches systemic circulation. Regulators evaluate it through measured exposure, commonly the area under the concentration-time curve (AUC), peak concentration (Cmax), and time to that peak (Tmax). The FDA's 2022 guidance frames bioavailability as a product-specific question that requires an appropriate study design.¹ A package label or delivery-route diagram cannot substitute for human pharmacokinetic data.

This distinction matters to me as a pharmacist and formulator. I chose a thin-film platform because it can reduce swallow burden, make a unit dose portable, and create a controlled disintegration experience. Those are defensible design goals. I would not turn them into a claim that every ingredient crosses the oral mucosa or that every strip outperforms every capsule.

Myth 1: Does sublingual always mean better absorption?

No. Sublingual delivery can avoid gastrointestinal degradation and hepatic first-pass metabolism for the portion of a dose that crosses the oral mucosa. A useful portion may still fail to cross.

Wang and Chow's 2014 review identifies the constraints directly: the sublingual region has a small absorptive area, transport is mainly passive, residence time is short, and local irritation can limit formulations.² Zhang and colleagues similarly concluded that not all drugs are suitable for oral mucosal administration because both mucosal properties and the molecule's physicochemical properties matter.³

The word “sublingual” also describes placement, not proof of uptake. A product may dissolve under the tongue while much of its dose mixes with saliva and is swallowed. That swallowed fraction follows the gastrointestinal route. To claim improved systemic exposure, a finished product needs comparative pharmacokinetic evidence.

Small, potent molecules with suitable solubility and membrane permeability are generally better candidates than bulky, highly polar, unstable, or high-dose compounds. Dose loading is a practical constraint too. A comfortable thin film has limited mass and area. Trying to force a gram-scale ingredient into that platform can damage disintegration, mouthfeel, dose uniformity, or all three.

Myth 2: Are all fast-dissolving products absorbed in the mouth?

No. Fast disintegration and transmucosal absorption are different events.

An oral film can disintegrate quickly and release its contents, but release is only the first step. The active must dissolve in saliva, remain at the mucosa long enough, partition into tissue, cross the epithelial barrier, and enter local blood flow. Material that is swallowed may instead be absorbed in the intestine.

The 1995 Biopharmaceutics Classification System paper by Amidon and colleagues established why this matters for conventional oral absorption: dissolution and intestinal permeability are fundamental variables controlling the rate and extent of uptake.⁴ Changing the format cannot repeal either variable. A rapidly dissolving compound with poor permeability may still be poorly absorbed.

The same formulation logic applies in the mouth. Polymer choice affects hydration and residence. pH influences ionization. Taste masking can change the excipient system. Saliva volume and user behavior affect contact time. Reviews of oral thin films describe accurate unit dosing, portability, ease of administration, and the potential for rapid delivery, but they also emphasize that composition, manufacturing, packaging, and evaluation determine performance.⁵⁶

For MIHIYO Labs, this is why “dissolves fast” is not the endpoint. The film has to remain intact in its package, separate cleanly, feel acceptable in the mouth, release consistently, and carry an ingredient that makes sense at the available dose. A short disintegration time is one specification among several.

Myth 3: Does bypassing first-pass metabolism create a fixed multiplier?

No. There is no scientifically defensible rule that sublingual delivery gives every ingredient “10x absorption.”

First-pass metabolism is presystemic loss in the intestinal wall and liver before an absorbed dose reaches general circulation. Avoiding it can matter greatly for some molecules and very little for others. The size of the benefit depends on how much first-pass loss the swallowed ingredient normally experiences, how much of the new dose actually crosses the mucosa, and whether the formulations deliver comparable amounts.

That makes a route-wide multiplier meaningless. Even two formulations using the same route can produce different AUC, Cmax, and Tmax because their excipients, particle state, pH, dose, and release behavior differ. FDA guidance therefore asks sponsors to characterize the specific products under defined conditions rather than infer equivalence from format names.¹

If a marketer gives an absorption multiple, ask four questions: compared with what formulation, at what dose, for which ingredient, and measured in which human study? Without those details, the number is advertising shorthand rather than pharmacokinetics.

Myth 4: Does liposomal solve every absorption problem?

No. Liposomes can help selected compounds, but “liposomal” is not a single standardized performance level.

Liposomes are lipid vesicles that can carry water-soluble material in an aqueous core and fat-soluble material within a lipid bilayer. That architecture can protect an ingredient, improve dispersion, or change its interaction with the gastrointestinal environment. It can also face structural instability during digestion and limited passage across intestinal barriers.

Lee's 2020 review found that oral liposomes had plausible advantages for poorly water-soluble drugs but also major limitations: instability in the gastrointestinal tract, poor epithelial permeability due partly to particle size, and a literature base weighted toward in-vitro rather than human evidence.⁷ The proper conclusion is ingredient- and formulation-specific, not category-wide.

A useful human example shows both promise and proportion. In a 2024 randomized, double-blind crossover trial of 27 adults, a specific 500 mg liposomal vitamin C product increased plasma Cmax by 27% and AUC over 24 hours by 21% compared with standard vitamin C. Leukocyte Cmax rose 20% and leukocyte AUC rose 8%.⁸ That is evidence for that product under those study conditions. It is not evidence that every liposomal supplement is superior, and it is far from a universal tenfold effect.

What can each dosage form honestly claim?

This table is the standard I use when reading dosage form marketing. Format tells me what a product may be engineered to do. Testing tells me whether the finished product does it.

How should buyers evaluate an absorption claim?

Start with the active ingredient, not the format badge. Ask whether the molecule is stable, soluble, permeable, and useful at the stated dose. Then look for evidence on the exact formulation.

A strong claim names the comparator and reports at least one pharmacokinetic outcome. “AUC was 21% higher than 500 mg standard vitamin C in a 27-person crossover trial” is interpretable.⁸ “Absorbs better” is not. A clinical outcome is a separate question again: higher blood exposure does not automatically mean a meaningful benefit for every user.

Check whether the evidence is human, animal, or laboratory work. In-vitro dissolution and cell models help formulate hypotheses, but they do not establish human exposure. Look for dose matching, crossover design when appropriate, sampling long enough to capture the curve, and disclosure of the tested product.

Finally, separate convenience from pharmacokinetics. Convenience can be valuable even when exposure is unchanged. A water-free unit dose may fit a commute better. A capsule may hold a larger dose more efficiently. A liquid may serve someone who needs flexible measurement. The best form is the one that matches the ingredient, the user, and the evidence.

What are the honest limits of an oral dissolving strip?

An ODS is not suitable for every supplement. Limited film area constrains high-dose ingredients. Saliva can shorten contact time. Swallowing part of the dose can reduce the fraction available for mucosal uptake. Taste masking and permeation goals can conflict with comfort. Moisture protection adds packaging demands.

Those constraints shape our product decisions. MIHIYO's Energy + Focus, Mood + Stress, and Sleep Support strips use a portable unit-dose format, but the format itself is not evidence of superior clinical effect. Our cited literature concerns ingredients and dosage-form principles, not finished MIHIYO products.

Readers who want the underlying concepts can review what bioavailability means on a supplement label and how the oral mucosa absorbs active compounds. Those concepts are more useful than any route-wide slogan.

Bottom line on supplement dosage form myths

Supplement dosage form myths become persuasive when a real mechanism is stretched into a universal promise. Sublingual delivery can reduce first-pass exposure for suitable molecules. Liposomes can improve delivery for certain formulations. Fast disintegration can improve convenience. None of those statements proves a fixed absorption multiple.

The pharmacology-first rule is straightforward: identify the molecule, dose, formulation, comparator, and human endpoint. Until those five pieces are present, treat “10x,” “all sublingual,” and “liposomal solves everything” as claims waiting for evidence.

References

¹: U.S. Food and Drug Administration. (2022). Bioavailability Studies Submitted in NDAs or INDs — General Considerations. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-studies-submitted-ndas-or-inds-general-considerations> ²: Wang Z, Chow MSS. (2014). Overview and appraisal of the current concept and technologies for improvement of sublingual drug delivery. Therapeutic Delivery. PMID: 25287387. DOI: 10.4155/tde.14.50. <https://pubmed.ncbi.nlm.nih.gov/25287387/> ³: Zhang H, Zhang J, Streisand JB. (2002). Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clinical Pharmacokinetics. PMID: 12126458. DOI: 10.2165/00003088-200241090-00003. <https://pubmed.ncbi.nlm.nih.gov/12126458/> ⁴: Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. PMID: 7617530. DOI: 10.1023/A:1016212804288. <https://pubmed.ncbi.nlm.nih.gov/7617530/> ⁵: Kathpalia H, Gupte A. (2013). An introduction to fast dissolving oral thin film drug delivery systems: a review. Current Drug Delivery. PMID: 24274635. DOI: 10.2174/156720181006131125150249. <https://pubmed.ncbi.nlm.nih.gov/24274635/> ⁶: Ruchika, Khan N, Dogra SS, Saneja A. (2024). The dawning era of oral thin films for nutraceutical delivery: From laboratory to clinic. Biotechnology Advances. PMID: 38615985. DOI: 10.1016/j.biotechadv.2024.108362. <https://pubmed.ncbi.nlm.nih.gov/38615985/> ⁷: Lee MK. (2020). Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches. Pharmaceutics. PMID: 32183185. DOI: 10.3390/pharmaceutics12030264. <https://pubmed.ncbi.nlm.nih.gov/32183185/> ⁸: Davis JK et al. (2024). Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes: a double-blind, placebo-controlled, randomized trial. European Journal of Nutrition. PMID: 39237620. DOI: 10.1007/s00394-024-03487-8. <https://pubmed.ncbi.nlm.nih.gov/39237620/>

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.